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ABSTRACT: Pteridine reductase-1 (PTR1) is a promising drug target for
the treatment of trypanosomiasis. We investigated the potential of a previously
identified class of thiadiazole inhibitors of Leishmania major PTR1 for activity
against Trypanosoma brucei (Tb). We solved crystal structures of several
TbPTR1-inhibitor complexes to guide the structure-based design of new
thiadiazole derivatives. Subsequent synthesis and enzyme- and cell-based assays
confirm new, mid-micromolar inhibitors of TbPTR1 with low toxicity. In
particular, compound 4m, a biphenyl-thiadiazole-2,5-diamine with IC50 = 16
μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate
reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC50
value. In addition, the antiparasitic activity of the combination of 4m and MTX
was reversed by addition of folic acid. By adopting an efficient hit discovery
platform, we demonstrate, using the 2-amino-1,3,4-thiadiazole scaffold, how a
promising tool for the development of anti-T. brucei agents can be obtained.
■ INTRODUCTION
According to theWorld Health Organization (WHO), neglected
tropical diseases afflict over 1 billion people.1 Among them,
parasitic infections caused by trypanosomatids represent a major
challenge. Kinetoplastea is a class of flagellated parasitic protists,
which includes various human pathogens transmitted by insect
vectors. Diseases that result from kinetoplastid infections include
human African trypanosomiasis (HAT; also known as African
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sleeping sickness), which is caused by Trypanosoma brucei
gambiense and T. brucei rhodesiense, Chagas disease caused by
Trypanosoma cruzi, and various forms of leishmaniasis caused
due to infection with different species of Leishmania.2 Sleeping
sickness is found across sub-Saharan Africa and evolves in two
phases. The parasite first reaches the bloodstream and the
lymphatic system, where it multiplies. At a later stage, the parasite
crosses the blood−brain barrier, reaching the central nervous
system and leading to death if untreated.3 Therefore, therapies
should be able to cure at least one of the two stages or both.
Pentamidine and suramin are first choice drugs for the treatment
of HAT. These drugs are specific for the first stage of pathology
but they are completely ineffective in the second neuronal stage.
Eflornithine, either in monotherapy or in combination with
nifurtimox, is approved for second-stage treatment of HAT
caused byT. b. gambiense.4 For the latter stage, melarsoprol is also
still used despite its high toxicity.5 However, all of the drugs
mentioned above have problems relating to poor efficacy,
difficulties in administration, and side effects. In addition, drug
resistance is also emerging. Thus, there is an urgent need to
discover new improved and affordable drugs.3 A target-based
drug-discovery approach is a promising strategy for the discovery
of new treatments for neglected diseases6 and has been
successfully exploited for the development of eflornithine (an
inhibitor of ornithine decarboxylase).7 Other targets, such as N-
myristoyltransferase,8 farnesyl transferase,9 trypanothione re-
ductase,10 and cathepsin L,11 have been validated in T. brucei
(Tb), but no drugs acting on these targets have yet been
approved for the treatment of HAT. One approach, successfully
used in the treatment of some bacterial infections12 and
malaria,13 could entail the use of drugs that target enzymes
involved in folate metabolism. Targeting dihydrofolate reductase
(DHFR) alone does not allow for successful antitrypanosomatid
therapy because of the presence of pteridine reductase-1
(PTR1). PTR1 is a reduced nicotinamide adenine dinucleotide
phosphate (NADPH)-dependent short-chain dehydrogenase/
reductase (SDR) mainly involved in the reduction of conjugated
and unconjugated pterins, such as biopterin.14,15 PTR1 is
responsible for the production of 10% of tetrahydrofolate
required by the cell, and its expression is increased when parasite
DHFR is inhibited by antifolate drugs. PTR1 thus provides the
reduced folate necessary for parasite survival, thereby contribu-
ting to treatment failure.16,17 PTR1 knockdown studies
performed by RNA interference methodologies on blood stream
form T. brucei compromised parasitic growth in vitro and in an
animal host.17,18 This evidence supports the importance of PTR1
for parasitic survival and indicates that it is a promising drug
target for the treatment of HAT. However, TbPTR1 inhibitors
developed to date have limited antiparasitic activity against T.
brucei.6,15,19−23 In our previous work, we have identified
thiadiazole derivatives as a new class of Leishmania major
PTR1 (LmPTR1) inhibitors that showed synergistic activity in
combination with pyrimethamine (a DHFR inhibitor) against
both L. major and Leishmania mexicana promastigotes.24,25 The
same behavior was observed with another PTR1 inhibitor class,
namely pteridines, tested against the same Leishmania species.
Thus, the emerging concept was that the selective PTR1
inhibitor alone did not show antiparasitic activity, and only the
combination with a DHFR inhibitor, such as pyrimethamine,
allowed the antiparasitic activity detection.26 In the present work,
we sought to exploit the thiadiazole scaffold as a source of new
inhibitors of TbPTR1, thereby targeting the folate/biopterin
pathway with potential for activity against the parasite in
combination with DHFR inhibitors. Therefore, we focused
mainly on compounds that showed PTR1 inhibition and no/low
antiparasitic activity to exploit the above combination concept.
We have established an efficient hit discovery platform, which
has a sound foundation in drug discovery that made use of a
combination of computational design, organic synthesis, X-ray
crystallography, enzyme inhibition, and antiparasitic activity
assays as well as early-toxicity studies. The chemical starting
points of the present study originated from a screen of the
previously tested thiadiazole library24 against TbPTR1 and the T.
brucei parasite. We then determined five ternary crystal structures
of TbPTR1 in complex with the cofactor NADP+ and thiadiazole
compounds, providing crucial data to support the design of
improved inhibitors. Four new compound series, including a
total of 57 compounds based on the 2-amino-1,3,4-thiadiazole
scaffold, were designed, synthesized, and evaluated against
TbPTR1. In addition, structure−activity relationships (SAR)
for TbPTR1 were derived from comparison of computational
docking results and crystallographic analyses. Initial toxicity
assessments were carried out with a panel of five assays in high
throughput screening (HTS) format. All compounds were
evaluated for in vitro antiparasitic activity by phenotypic HTS
against T. brucei. Finally, the most potent TbPTR1 inhibitors
were assayed in combination with the known DHFR inhibitor
methotrexate (MTX) to evaluate the efficacy of the simultaneous
inhibition of DHFR and PTR1 on T. brucei parasite growth.
■ RESULTS AND DISCUSSION
Selection of Compounds I−IV and X-ray Crystallo-
graphic Analyses. Compounds I−X (Table S1) of the original
thiadiazole library were selected for testing against TbPTR1,
based on molecular diversity and compound availability.24,27
Only compounds II−IV showedmeasurable inhibition constants
(Ki) against TbPTR1 in the range of 48−88 μM(IIKi 48 μM; III
Ki 53 μM; and IV Ki 88 μM), thus behaving as weak TbPTR1
inhibitors (Figure 1 and Table S1). Compound I showed an EC50
value of 35 μM in the T. brucei parasite growth inhibition assay
and no detectable inhibition of TbPTR1 at 100 μM. We could
not detect antiparasitic activity for compounds II and III at
concentrations up to 50 μM. Compound IV was the only
compound with low PTR1 inhibition and parasite growth
inhibition (TbPTR1 Ki 88 μM and T. brucei EC50 170 μM).
Compounds V−X showed low inhibition of TbPTR1 (Table S1)
at the tested concentration and no detectable growth inhibition
of the T. brucei parasite at the concentration tested (50 or 100
μM). Compounds I−IV showed high toxicity against mamma-
lian cells with selectivity indices (EC50 mammalian/EC50 T.
brucei) lower than 1 (Table S1).
We carried out crystallographic analyses of TbPTR1-inhibitor
complexes to identify possible templates for medicinal chemistry
exploration. Previous docking studies19 indicated that the
thiadiazole ring would form a stacking interaction between the
nicotinamide ring of NADP+ and Phe113 of LmPTR1
(corresponding to Phe97 of TbPTR1) and that lack of a cofactor
results in a disordered binding pocket.28 I−X were used for
crystallization trials with TbPTR1, and for four compounds I−IV
(Figure 1) ternary complex structures [PDB ID: 2YHI (I);
2YHU (II); 4WCF (III); and 4WCD (IV)] were determined at
high resolution (1.80, 2.01, 1.68, and 1.93 Å, respectively).
Crystallographic statistics are presented in Table S2 in the
Supporting Information.
The crystal structures are isomorphous with an asymmetric
unit consisting of a homotetramer, the functional unit of
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TbPTR1. Each subunit has the typical structure of the short-
chain SDR superfamily: a single α/β-domain constructed from a
seven-stranded parallel β-sheet sandwiched between two sets of
α-helices. The active site is an L-shaped depression, formed
primarily by one subunit and blocked at one end by a partner
subunit. NADP+ binds in an extended conformation to form the
binary complex essential for substrate/ligand binding. Analyses
of the complexes with I−IV shows that the interaction of
compounds I−III is mainly driven by the thiadiazole moiety,
which is indeed sandwiched between the nicotinamide of
NADP+ and Phe97 (Figure 2A−C). However, for compound
IV (Figure 2D), it is the bulkier benzotriazole substituent that
stacks in this position, placing the thiadiazole moiety to
participate in an edge−face interaction with Trp221 on the
periphery of the active site. The crystal structure of TbPTR1−
NADP+−I shows that the chloro-ethyl moiety of the inhibitor
establishes a halogen bond with the π-system of Trp221 and van
der Waals interactions with Val206, Pro210, and Met213. The
amino group is H-bonded to Tyr174 OH and to the
nicotinamide ribose, whereas a water molecule mediates the
interactions with the side chain of Ser95 and the cofactor
phosphate (Figure 2A). Because of the increased bulk of II and
III, these compounds are placed further toward the cofactor, and
the amino group displaces the ordered water observed in the
TbPTR1−NADP+−I active site (Figure 2B,C). A H-bond is
formed between Tyr174 and nitrogen at position 3 of the
thiadiazole ring of compound II (not shown). The same nitrogen
is within the H-bonding distance of the ribose moiety of the
Figure 1. Chemical structures of previously synthesized thiadiazoles (I−IV) crystallized with TbPTR1−NADP+ and the newly designed thiadiazoles
(series 1−4).
Figure 2. Noncovalent interactions involving thiadiazole derivatives (stick representation, green carbons) in the TbPTR1 active site: (A) compound I,
(B) compound II, (C) compound III, and (D) compound IV. The thiadiazole ring in all compounds (except IV) is sandwiched between the
nicotinamide ring of cofactor NADP+ (black carbons) and the phenyl ring of Phe97. H-bond interactions are represented by black dashed lines; water
molecules are shown as red spheres. Model atoms except for carbons are color coded; protein carbons are white, oxygen red, sulfur yellow, chlorine gray,
and phosphorous magenta. The protein backbone is drawn as a white cartoon. Note S-oxycysteine 168 (CSX) in (B,C). Interaction distances are
reported in Table S2.1 in the Supporting Information.
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cofactor. This interaction is also visible in the complex with
compound III (Figure 2C). Moreover, here the amino group on
the aminopyridine ring is H-bonded to Asp161 and Tyr174 and
participates in water-mediated interactions with the same
aspartate and the carbonyl of Gly205 (not shown). Comparison
between the binding modes of compounds II−III and folate
(PDB: 3BMC; TbPTR1−NADP+−folate complex) reveals that
thiadiazole overlaps 2-amino-4-oxo pyrimidine of folic acid (see
Figure S1 in Supporting Information). Notably, the amino group
at position 2 of compounds II and III superimposes on the amino
group in position 2 of the pteridine, forming similar H-bonds
with the enzyme and the cofactor. In the case of II, the thiophene
ring forms a T-shaped stacking interaction with Trp221 (Figure
2B). In the structure of the ternary complex TbPTR1−NADP+−
IV (Figure 2D), although similar to the other inhibitor
complexes, one active site of the tetramer does not possess
electron density for either the cofactor or the inhibitor.
Moreover, in this subunit, the loop adjacent to the active site,
including residues from 209 to 217, is disordered and hence
excluded from our model. In addition to the different stacking
arrangement described for compound IV, a series of polar
interactions stabilize the benzotriazole position. The nitrogen at
position 1 forms a H-bond with NADP+ phosphate, and cofactor
ribose hydroxyl is within the hydrogen bonding distance of the
benzotriazole nitrogens at positions 2 and 3 that are further
involved in weak interactions with the hydroxyl groups of Ser95
and Tyr174, respectively.
Despite the modest biological profile of compounds I−IV as
TbPTR1 inhibitors, we sought to explore the potential of this
class of compounds as TbPTR1 inhibitors and anti-T. brucei
agents, guided by the structural binding mode of the thiadiazole
scaffold within TbPTR1 observed in the four resolved crystallo-
graphic complexes. The design of new thiadiazole derivatives
focused on the optimization of the molecular interactions
described herein, exploiting the most reliable binding mode of
compounds I−III. In our design, we aimed at identifying a
TbPTR1 inhibitor that can show a synergistic effect in
combination with a DHFR inhibitor; therefore, the antiparasitic
activity of the thiadiazole derivative per se was not considered to
be a requirement for the synergistic combination effect.
Design of 2-Amino-1,3,4-thiadiazole Derivatives. To
initiate the design of new 2-amino-1,3,4-thiadiazole derivatives,
molecular interaction fields were calculated (SiteMap27) to
understand how the ligands complement the receptor and how
extensions into adjacent regions could promote binding. The
structures of TbPTR1 with compounds I−IV show similar
interaction fields in the active site. However, we opted to exploit
for the development of the 2-amino-1,3,4-thiadiazole core, the
binding mode of compounds I−III, as it is conserved in three of
the four X-ray crystal structures, thus providing a reliable premise
for the structure-based inhibitor design. These structures reveal a
large hydrophobic region between Phe97 and the nicotinamide,
extending toward the surface of the protein next to Trp221,
which closes the TbPTR1 active site (Figure 3). Two distinct
hydrophilic regions were also identified, which can be further
divided into regions favorable for H-bond donors and acceptors.
One of these is located in the depth of the catalytic site, and the
phosphate groups of the NADP+ cofactor, Ser95 and Tyr174,
delineate it. This region is split into a region favorable for H-bond
donors, which is in part addressed by the amino group in position
2 on the main core scaffold, and a small favorable interaction site
for H-bond acceptors. The second hydrophilic region is close to
Asp161 and represents an additional favorable interaction site for
H-bond donors. Therefore, extending from the 2-amino-1,3,4-
thiadiazole core, which establishes key interactions, we modified
position 5 of the ring with substituents designed to interact with
the residues lining the pocket of the binding site. Four series of
compounds were synthesized (Figure 1). In the first two series, a
phenyl or heteroaromatic ring (compounds 1a−t, Chart 1) or a
biphenyl system (compounds 2a−g, Chart 2) was bound to the
thiadiazole ring to fill the large hydrophobic region located next
to the catalytic site. In the third series (compounds 3a−k, Chart
3), the aromatic ring was spaced with a short aliphatic chain (one
to three carbon atoms) to reach the position occupied by the p-
amino-benzoic acid (PABA) ring of the natural folic acid
substrate. The only exception is compound 3i, which has the
distal aromatic ring replaced by dimethylamine; it was
commercially available and was purchased. Compound II
(showing the lowest Ki value in the initial screen) was
resynthesized as an internal reference (3k). Then, to closely
match the nitrogen system of the pteridine moiety of the natural
PTR1 substrate and to potentially address the additional region
favorable for H-bond donors close to Asp161, a fourth series of
thiadiazoles was designed (compounds 4a−s, Chart 4),
introducing nitrogen in position 5 of the thiadiazole ring.
Chemistry. Four series of thiadiazoles were synthesized: 5-
aryl-2-amino-1,3,4-thiadiazoles (1a−t); 5-biphenyl-2-amino-
1,3,4-thiadiazoles (2a−g); 5-alkyl-2-amino-1,3,4-thiadiazoles
(3a−k), and 2,5-diamino-1,3,4-thiadiazoles (4a−s). For the
synthesis of compounds 1a−t, 2a−g, and 3a−k, the closure of
the thiadiazole ring was optimized and four synthetic pathways
were developed (Scheme 1). The choice of the synthetic method
was constrained by the compatibility between the sensitive
chemical functions present in the molecule and the strong
oxidizing and dehydrating agents necessary for the thiadiazole
ring closure. Method A, depicted in Scheme 1, requires the
condensation of the appropriate alkyl/aryl carboxylic acid with
thiosemicarbazide in the presence of phosphorus-(V)-oxachlor-
ide (POCl3).
29 Compounds 1i, 1j−k, 1o, 2b, 3a, 3c−d, and 3f−g
Figure 3. Energetically favorable interaction sites in the TbPTR1
binding site computed using SiteMap for the crystal structure with
compound III (4WCF). Favorable regions for hydrophobic groups are
shown by yellow isocontours (at −0.5 kcal/mol); for hydrogen bond
donors and acceptors, they are shown by isocontours (at −8 kcal/mol)
in blue and red, respectively. NADP+ (in black) and some important
residues delineating the pocket (in white) are shown in stick
representation. The 2-amino-1,3,4-thiadiazole moiety (in ball and
stick, green carbons) of compound III is displayed for reference.
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were synthesized following the described procedure. It was not
possible to obtain the thiadiazoles 1a, 3e, 3h, and 3j−k in the
presence of POCl3; for these compounds, the use of
concentrated sulfuric acid as a dehydrating agent at room
temperature overnight allowed the final compounds to be
obtained in good yield (method B, Scheme 1).29 The synthesis of
thiadiazoles 1b, 1t, 3b, and intermediate 6 required milder
experimental conditions because several attempts with sulfuric
acid or POCl3 led to decomposition. Thus, the thiadiazole ring
closure was in this case performed by condensation between
alkyl/aryl nitrile 9a−d and thiosemicarbazide in concentrated
trifluoroacetic acid at 60 °C (method C, Scheme 1).29
Thiadiazole 6 thus obtained was not isolated and was instead
directly used in the next step without further purification. When
it was not possible to use these strong oxidizing and dehydrating
agents because of the presence of sensitive chemical functions, an
alternative synthetic route that requires oxidation of aryl-
thiosemicarbazone, prepared from the relative aldehydes, with
an ethanolic solution of FeCl3 at 60 °C was shown to be
successful (method D, Scheme 1).29 Ureido-thiadiazoles 1p−q
were prepared through a reaction of 1b and 6, respectively, with
dimethylcarbamyl chloride in dry dichloromethane (DCM)
(Scheme 2). Because it was not possible to directly prepare
catecholic thiadiazole with any of the experimental procedures
described above, 3′,4′-dihydroxy-phenyl-1,3,4-thiadiazole (1d)
and 3′,4′,5′-trihydroxy-phenyl-1,3,4-thiadiazole (1f) were ob-
tained through demethylation of the respective methoxylated
thiadiazoles 1c and 1e, using boron tribromide (Scheme 3).
Finally, compounds 4a−s were all synthesized through aromatic
nucleophilic substitution between the appropriate commercial
alkylamine and 5-amino-2-bromo-1,3,4-thiadiazole (Scheme 4).
Nitriles 9a (benzylcyanide) and 9b [4-(aminomethyl)-
benzonitrile] were commercially available and used as purchased.
3-(4-Methoxyphenyl-)pyridin-2-carbonitrile (9c) was instead
prepared as depicted in Scheme 5: 3-bromo-5-pyridincarbox-
aldehyde was converted first to 3-bromo-5-pyridincarbonitrile
(7) with concentrated ammonia in tetrahydrofuran (THF) at
room temperature, using iodine as the oxidant.30 Then, 7 was
reacted with 4-methoxyphenylboronic acid through the standard
Suzuki reaction to obtain biphenyl nitrile 9c.31 Similarly, for the
synthesis of 3-(aminomethyl)benzonitri le (9d), 3-
(bromomethyl)benzonitrile was reacted with potassium phtha-
limide under standard SN2 conditions to give the corresponding
phthalimide 8. Phthalimide was then converted to amine with
Chart 1. 2-Amino-1,3,4-thiadiazoles Containing a Substituted Aryl Moiety in Position 5a
aStandard deviation is within ±10% of the value. NI; no inhibition.
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aqueous hydrazine to give the desired nitrile 9d (Scheme 5).
Finally, for the synthesis of thiosemicarbazones 11a−o,
aldehydes 10a−e and 10i−j were commercially available and
used as purchased. Biphenylaldehydes 10k−o were prepared
using the Suzuki reaction between 3-bromobenzaldehyde and
the appropriate phenylboronic acid. The same synthetic reaction
was performed between 3-(bromomethyl)benzaldehyde and
phenylboronic acid or 4-cyanophenylboronic acid to give benzyl-
benzaldehydes 10f and 10g, respectively. Aldehyde 10h was
instead prepared via SN2 reaction between p-hydroxybenzalde-
hyde and 3,4-dichlorobenzylchloride. Thus, aryl aldehydes 10a−
o were condensed with thiosemicarbazide to obtain the
respective aryl-thiosemicarbazones (11a−o) (Scheme 6).
PTR1 Inhibition Studies. All 57 new thiadiazoles 1a−t, 2a−
g, 3a−k, and 4a−s were evaluated for their inhibitory activity
against TbPTR1. Compounds displaying a percentage of
inhibition against TbPTR1 above 30% at 50 μM were further
analyzed in dose−response experiments between 0.001 and 100
μM to enable the determination of their IC50 values. The IC50
value of pyrimethamine (IC50 = 0.09 μM against TbPTR1), a
DHFR inhibitor also able to inhibit PTR1, was measured
routinely as a standard. The activity data of the entire panel of
compounds are reported in Charts 1−4. The general activity
profile of the studied compounds is shown in Figure 4. Among
the 57 thiadiazoles synthesized, 1f, 4c, 4e−f, 4h−i, 4m−o, and
4q were associated with IC50 values in the range of 16 to 112 μM
(Charts 1−4), resulting in a 2 to 12-fold improved inhibition
effect toward TbPTR1 in comparison to the initial screening hits
II−IV (IC50 > 200 μM).With the exception of 1f (TbPTR1, IC50
41 μM), the most active TbPTR1 inhibitors belong to the 2,5-
diamino-1,3,4-thiadiazoles (series 4) with the best compound
4m showing an IC50 of 16 μM. TbPTR1 and TbDHFR use
similar substrates such as dihydrofolic acid; thus, PTR1 inhibitors
can also interact with DHFR. Therefore, to evaluate the potential
dual PTR1 and DHFR inhibition, all compounds were tested
against TbDHFR. However, none of the compounds showed any
significant inhibitory activity against TbDHFR (Table S3). The
compounds that showed the best inhibitory activity against
TbPTR1 were selected for further studies.
Crystallographic Studies of Compound 4c. Cocrystalli-
zation trials were performed with ten thiadiazole compounds that
showed the best inhibition against TbPTR1 (1f, 4c, 4e−f, 4h−i,
4m−o, and 4q). Only compound 4c, belonging to the fourth
series, resulted in a ternary complex at an acceptable resolution.
4c is a comparatively modest inhibitor of TbPTR1 showing an
IC50 of 112 μM. The structure of the complex TbPTR1−
NADP+−4c was determined to 1.92 Å resolution (PDB ID:
5IZC). Statistics for the data collection and refinement are
presented in Table S2 in the Supporting Information. Ligand
placement in the active site and key interactions are depicted in
Figure 5. 4c adopts the same binding mode in all four subunits of
the enzyme, only with differing orientations of the thiophene
ring. The electron density for 4c is best defined in subunits A and
D. The 4c thiadiazole ring binds in a π-sandwich between the
nicotinamide of NADP+ and Phe97, as previously described. The
2-amino group on the thiadiazole of 4c is within the hydrogen
bonding distance of both NADP+ phosphate and Ser95 OH. The
thiadiazole nitrogen in position 3 forms a bifurcated interaction
with the NADP+ ribose OH and Tyr174 OH. Furthermore, the
thiadiazole nitrogen in position 4 is within the hydrogen bonding
distance of Tyr174 OH. The thiophene moiety of 4c lodges in
the hydrophobic cavity defined by Cys168, Val206, Leu209,
Met213, and Trp221. The above interactions are retained in all
four subunits of the TbPTR1 tetramer. Cys168 is chemically
modified to S,S-(2-hydroxylethyl)thiocysteine (defined also as
CME in Figure 5) because of the reaction with β-
mercaptoethanol present in the purification buffer.
Chart 2. 2-Amino-1,3,4-thiadiazoles Substituted with a Biphenyl System in Position 5a
aStandard deviation is within ±10% of the value.
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SAR for TbPTR1 Inhibition. Although the design of the 57
compounds was largely based on the crystal structures available
for compounds I−IV, the observed PTR1 inhibition potency did
not reflect the expected effects of the structural modifications.
This suggests that the binding mode observed in the crystal
structures might be altered for the modified compounds.
Therefore, to explore possible alternative binding modes, we
docked all synthesized compounds in the TbPTR1 binding site.
Combining the predicted binding modes with the crystal
structures enabled us to explain the SAR for the compounds’
inhibitory potential against TbPTR1. Common interactions,
such as stacking of the thiadiazole core moiety between Phe97
and nicotinamide, were generally reproduced in docking.
Because of the small size of the ligand core, rotation within the
pocket did however result in different hydrogen bonding
patterns, for example, involving the cofactor phosphate and
ribose, Ser95, Asp161, and Tyr174, as indicated by differing
arrangements of the thiadiazole core in Figure 6B−D.
A direct connection of the thiadiazole core with an aryl moiety,
as in series 1 (Chart 1: 5-aryl-1,3,4-thiadiazoles), may lead to a
competition for the stacking position in the TbPTR1 binding
site, which pushes the core moiety closer to the cofactor to
introduce unfavorable contacts, as observed in almost all docked
complexes of these compounds. Series 1 compounds consis-
tently show low TbPTR1 inhibition. Only compound 1f, bearing
a pyrogallol substituent, presents a moderate IC50 value of 41
μM. We hypothesize that the pyrogallol moiety occupies the
stacking position and forms several H-bonds with Tyr174 and
cofactor phosphates and ribose (Figure 6A). Because this
alternative binding mode is specific for 1f, it may explain the
observed activity. Series 2 and series 3 compounds only yielded
<47% inhibition of TbPTR1 at 50 μM. In series 2 (Chart 2: 5-
biphenyl-1,3,4-thiadiazoles), the elongated conformation of the
compounds fits the binding pocket poorly, whereas in series 3
(Chart 3: 5-aryl-aliphatic-1,3,4-thiadiazoles), the long, flexible
aliphatic linkers tend to be disfavored and are often placed in a
polar and thus unfavorable environment, further leading to an
unfavorable placement of substituents. Series 4 (Chart 4: 2,5-
diamino-1,3,4-thiadiazoles) includes nine out of the nineteen
compounds that yielded >30% inhibition of TbPTR1 at 50 μM,
resulting in IC50 values in the range of 16−112 μM. Compounds
of this class typically have a linker of 2−3 atoms between
thiadiazole and further aryl substituents, including nitrogen in
position 5. The second amino-nitrogen thereby allows for further
favorable interactions, for example, with the carbonyl group of
the cofactor, Asp161, or Tyr174, as indicated by the bound
orientation of compound 4c in the crystal structure 5IZC (see
Figure 5). Hence, series 4 allows the exploitation of the
additional region favorable for H-bond donors, as identified by
the SiteMap calculations (see also Figure 3). Although
comparatively small compounds, such as 4i, show similar binding
modes to that observed in the crystallographic complex of 4c
(compare Figure S2A), larger compounds are locked in a binding
orientation closely resembling that of folic acid, as shown in
Chart 3. 2-Amino-1,3,4-thiadiazoles Substituted in Position 5 with an (Aryl-)aliphatic Chaina
aStandard deviation is within ±10% of the value. NI; no inhibition.
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Figure 6B−D. A substrate-like complex thereby seems to
correlate with enhanced activity because the docking mode of
the majority of actives in this class best matches the folic acid
orientation.
Compound 4m has a linked biphenyl system and is the most
active compound (TbPTR1 IC50 16 μM). The thiadiazole
position is stabilized by hydrogen bonding interactions with the
cofactor and Ser95, and the phenyl ring systems of 4m interact by
π−π interactions and hydrophobic contacts with Phe97, Met163,
Phe171, Tyr174, Met213, and Trp221. Notably, as shown in
Figure 6B, the biphenyl system adopts a substrate-like
orientation, with the first phenyl ring mimicking the PABA
moiety of folic acid and the second phenyl locking the compound
in that orientation by spatial restraints. Similar observations can
be made for compounds 4o (TbPTR1, IC50 25 μM) and 4e
(TbPTR1, IC50 31 μM). Interestingly, 4n (TbPTR1, IC50 62
μM) shows an identical binding mode to 4o but is about 3 times
less active. In summary, compounds that are able to bind in a
Chart 4. 2,5-Diamino-1,3,4-thiadiazoles Containing Variations on the N5-Linked Groupa
aStandard deviation is within ±10% of the value. NI; no inhibition.
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substrate-like orientation show the best TbPTR1 inhibition
profile. Despite the fact that direct correlation between the
docking score and the % inhibition or IC50 for the compounds
could not be observed, we were able to deduce likely near native
poses and describe a qualitative correlation between the observed
binding mode in the crystallographic complexes, the docking
results, and the anti-PTR1 activity of the compounds (“Docking
Protocol Validation”, Supporting Information). Visual inspec-
tion of the interaction pattern and comparison with crystal
structures were used to select the most likely poses, based on
experimental evidence.
Antiparasitic In Vitro Evaluation against Cultured T.
brucei. All compounds were evaluated for inhibitory activity on
growth of in vitro cultured T. b. brucei through a HTS assay (a
cell-based assay with a fluorescent readout) during a phenotypic
screening campaign. The antiparasitic activity is expressed as the
percentage of cell growth inhibition at 50 μM and is reported in
Charts 1−4. For the nine compounds (1b, 1d, 1f, 1m, 1n, 2d, 3f,
3h, and 4i) showing >75% inhibition, the EC50 was also
determined with results in the range of 0.8−58.0 μM. We
observed no correlation between TbPTR1 inhibition and
antiparasitic activity (Figure 7). The data distribution in Figure
7 highlights two distinct sets of compounds: cluster A includes all
thiadiazoles that showed antiparasitic activity with EC50 in the
range of 0.8−58.0 μM (1b, 1d, 1f, 1m−n, 2d−e, 3f, 3h, and 4i)
but had poor efficacy against the target enzyme (<50% inhibition
of TbPTR1 at 50 μM) and is therefore likely to have a different
target. On the other hand, cluster B comprises two compounds
(4m and 4o) that show the highest TbPTR1 inhibition (IC50 16
and 25 μM, respectively) but poor antiparasitic activity when
tested as single agents (Figure 7, Chart 4). In addition, neither
4m nor 4o is able to inhibit parasitic TbDHFR at 100 μM. We
were able to identify better T. brucei growth inhibitors with
respect to our starting compounds. In particular, compound 1b
showed 7.2-fold better activity with respect to compound I (EC50
0.8 μMand EC50 5.8 μM). All compounds were also evaluated for
in vitro antiparasitic activity against the intracellular amastigote
stage of L. infantum, but no compound showed antileishmanial
activity >50% inhibition at 50 μM (Table S3, Supporting
Information).32 The best compounds with anti-T. brucei activity
were 1b and 1f, but they did not show inhibition of TbPTR1.
Because of the lack of compounds exhibiting both TbPTR1
inhibition and antiparasitic activity, our interest turned to the
Scheme 1. Synthetic Methods Employed for the Thiadiazole Ring Closurea
a(a) POCl3, neat, 80 °C, overnight; (b) H2SO4 concn, neat, rt, overnight; (c) trifluoroacetic acid, neat, 60 °C, 6−12 h; and (d) FeCl3 (2 equiv),
EtOH aq 50%, 60 °C, 0.5−6 h.
Scheme 2. Synthesis of Dimethylcarbamyl Compounds 1p−
qa
aReagent and conditions: (a) dimethylcarbamyl chloride, DCM dry,
N2, rt, 24 h.
Scheme 3. Synthesis of Hydroxylated Compounds 1d and 1fa
aReagent and conditions: (a) BBr3 1.25 M in DCM, DCM dry, N2, 0
°C → rt, 1−3 h.
Scheme 4. Synthesis of 2,5-Diamino-1,3,4-thiadiazoles 4a−sa
aReagent and conditions: (a) Triethylamine (2.5 equiv), THF, refl., 6 h.
Scheme 5. Synthesis of Nitriles 9c−da
aReagent and conditions: (a) NH3 aq 35%, I2 (1.1 equiv), THF, rt, 1
h; (b) 4-methoxy-phenylboronic acid, Pd/C 10 mol %, Na2CO3 aq 1
M, dioxane, 60 °C, 24 h; (c) potassium phthalimide, dimethylforma-
mide (DMF), rt, 12 h; and (d) NH2NH2 aq, THF, rt, 24 h.
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evaluation of compounds 4m and 4o in combination with a
TbDHFR inhibitor.
Potentiating Effect of Thiadiazoles in Combination
with MTX. Given that inhibition of TbDHFR alone does not
effectively kill the parasite because of a bypass via TbPTR1, a
simultaneous inhibition of both enzymes should result in an
improved antiparasitic effect.31,32 MTX (a well-known DHFR
inhibitor) is a potent inhibitor ofTbDHFR (Ki = 15 nM)
33,34 that
exerts an inhibitory activity also against recombinant TbPTR1
(Ki = 50 nM). In standard T. brucei growth conditions, as in our
experiments, where the media is supplemented with 9 μM folic
acid, MTX is a poor antitrypanocidal agent showing an EC50 of
35 ± 3.0 μM, 1000 times higher than the reported EC50 of 0.012
μM with no folate supplementation.35−37
Scheme 6. Synthesis of Aldehydes 10a−o and the Respective Thiosemicarbazones 11a−oa
aReagents and conditions: (a) Pd/C 10 mol %, Na2CO3 aq 1 M, dioxane, 60 °C, 24 h; (b) K2CO3 (2.5 equiv), DMF, 120 °C, 2 h; (c) tetrakis 10
mol %, Na2CO3 (2 equiv), water/dioxane 1:1, 60 °C, 6 h; and (d) FeCl3 (2 equiv), EtOH aq 50%, 60 °C, 0.5−6 h.
Figure 4. Activity profile against T. b. brucei (y-axis) observed for the
newly synthesized thiadiazoles (series 1: purple line; series 2: red line;
series 3: green line; and series 4: blue line) against the percentage of
TbPTR1 inhibitory activity at 50 μM (x-axis).
Figure 5.Noncovalent interactions involving inhibitor 4c (green sticks)
in the TbPTR1 active site. The 4c thiadiazole ring is sandwiched
between the nicotinamide ring of the NADP+ cofactor and the phenyl
ring of Phe97, as for compounds I, II, and III. H-bonds are represented
by black dashed lines; water molecules are shown as red spheres. All
model atoms are color coded following atom types, except C atoms for
protein residues are in white, for NADP+ in black, and for the inhibitor in
green. The protein backbone is drawn as a white cartoon. Note the
modified Cys168 as S,S-(2-hydroxyethyl)thiocysteine (CME). Inter-
action distances are reported in Table S2.1 in the Supporting
Information.
ACS Omega Article
DOI: 10.1021/acsomega.7b00473
ACS Omega 2017, 2, 5666−5683
5675
We compared the antiparasitic activity of some selected
TbPTR1 inhibitors as single agents and in combination with
MTX, resulting in the selection of four compounds that
presented distinct TbPTR1 inhibition (4m, IC50 = 16 μM; 4o,
IC50 = 25 μM; 4h, IC50 = 70 μM, and 3k, IC50 > 70 μM), and
dose−response antiparasitic studies were performed. Com-
pounds 1m, 2d, and 2e were associated with 34−48%
antiparasitic activity at 50 μM, whereas all other compounds
yielded <30% antiparasitic activity. Therefore, the entire
compound library was considered associated with low activity
against T. brucei (Figure S3, Supporting Information). The
TbPTR1 inhibitors were combined with equimolar amounts of
MTX (the EC50 value for MTX against T. brucei was 35 ± 3.0
μM), and dose−response curves were determined (Figure 8).
Figure 6. Docking poses of compounds in TbPTR1. The reference crystal structure (PDB ID 2X9G) of TbPTR1 is shown in cartoon representation,
with important interacting residues in stick representation with gray carbons in complex with NADP+ (stick representation, black carbons). (A) Docked
pose of compound 1f (sticks, yellow carbons, 2x9g-1f_dockedcomplex.pdb in Supporting Information) shown with the crystallographic orientation of
compound IV (from PDB ID 4WCD, pale turquoise carbons) for reference. (B−D) Sample docking poses of compound 4m (sticks, orange carbons,
2x9g-4m_dockedcomplex.pdb in Supporting Information), 4o (sticks, brown carbons, 2x9g-4o_dockedcomplex.pdb in Supporting Information), and
4e (sticks, golden carbons, 2x9g-4e_dockedcomplex.pdb in Supporting Information) with folate from PDB ID 3BMC (sticks, dark gray carbons) shown
for reference. Hydrogen bonds are indicated by black dotted lines.
Figure 7.Correlation between the percentage of enzyme inhibition of the target TbPTR1 at 50 μM and antiparasitic activity against T. brucei performed
at the same concentration. (A) Thiadiazoles that showed antiparasitic activity with EC50 in the range of 0.8−58.0 μMbut poor efficacy against the target
enzyme. (B) Compounds 4m and 4o, which showed TbPTR1 inhibition but poor antiparasitic activity as single agents.
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The data show a measureable antiparasitic EC50 for the
combinations and, in particular, the EC50 of MTX was reduced
by a factor of 4.1 when combined with 4m (EC50 8.6 ± 1.1 μM,
Figures 8 and S4) and by a factor of 2 when combined with 4o
(EC50 17.5 ± 0.5 μM, Figures 8 and S4). Interestingly, only
compounds showing TbPTR1 inhibition (4m and 4o) were able
to potentiate MTX EC50. Although MTX can inhibit both PTR1
and DHFR enzymes, the observed potentiation effect can arise
from the enhancement of the dual inhibitory effect caused by
supplementary PTR1 inhibition induced by the thiadiazoles used
in the combination. In fact, despite the PTR1 inhibitory activity,
the administration of 50 μM of 4m alone did not show any
significant antiparasitic effect. Similarly, compounds 4o and 4c
showed low T. brucei cell inhibitory activity. In addition, an
increasing concentration of 4m induced an increasing inhibitory
effect of MTX in combination, indicating that potentiation
occurs. This potentiation is greater than the simple additive effect
(4m has no intrinsic antiparasitic activity); therefore, the potency
of the combination is much greater than the potency of the single
agents that compose it.
On the basis of these results, we expected to rescue the DHFR
activity and consequently, parasite vitality, by supplementing
with folic acid, the natural substrate of DHFR. Our compounds
display almost no inhibition of DHFR (Table S3). It is reported
that folic acid competes with MTX for DHFR, displacing it and
reversing DHFR inhibition on a cellular level.38 Folic acid supply
is in fact used in clinical settings to alleviate the toxicity of
MTX.39,40 We observed the same behavior in T. brucei cell
culture. After testing different folic acid concentrations, we
observed that the addition of 1 mM folic acid was able to reduce
the antiparasitic activity of MTX alone, safeguarding the cell
survival, without interfering with parasite growth (Figure 9A).
Focusing on compound 4m, which showed the best TbPTR1
IC50 value and potentiation of the antiparasitic activity of MTX,
we observed that supplementation with 1 mM folic acid was able
to rescue cell growth treated with 4m andMTX (Figure 9B). Our
data suggest that PTR1 inhibitors potentiate the antiparasitic
effect of MTX, probably by preventing the PTR1 bypass for the
reduction of folate.
Folic acid administration reverses the effect of MTX (by
binding both to DHFR and PTR1) up to almost the original
activity of MTX alone, but does not abrogate the effect of MTX
completely. This nonphysiological folate concentration could
reduce the antitrypanosomal potency of MTX through
competition for drug uptake.36 Thus, the low effect of MTX
on the parasite cells is due to a low amount of compound passing
into the cells, and as a consequence, there is a low amount of
MTX inside the cells and low inhibition of TbPTR1 and
TbDHFR. Instead the trans-membrane crossing of 4m and 4o is
different from that of MTX because they have a folate-unrelated
structure. This allows 4m to be competitive with respect to MTX
in the binding toward PTR1. Therefore, coadministering the
thiadiazole with MTX, the compound is delivered to the cell and
is available to induce supplementary inhibition on PTR1, thus
causing an overall potentiation effect. More experiments are
ongoing to clarify the potentiation effect of PTR1 inhibitors
using other classes of PTR1 inhibitors.
Early Compound-Mediated Toxicity and Liability
Studies. Independent of the effect of any antiparasitic potential
of compounds, they were evaluated using a panel of early-toxicity
assays comprising cytotoxicity (A549, human lung adenocarci-
noma epithelial cell line and WI-38, human lung fibroblasts),
mitochondrial toxicity (786-O, human renal carcinoma cell line),
hERG inhibition,31 cytochrome P450 inhibition (CYP1A2,
CYP2C9, CYP2C19, CYP2D6, and CYP3A4),31 and Aurora B
kinase inhibition. These experiments were performed using 10
μM of each compound and the output was expressed as %
inhibition, which is displayed as a heat map in Figure 10. An
acceptable profile for compounds at this stage in the drug-
discovery process should exhibit <30% inhibition at 10 μM in the
case of mitochondrial toxicity, hERG, CYP isoforms, and Aurora
B kinase, whereas the percentage of A549/WI-38 cell growth
should be >70%.32 Almost all evaluated compounds (series 1−
3) showed a safe profile, revealing that the thiadiazole scaffold has
a well-tolerated liability profile that can be further explored
during their development. Some compounds in series 4 showed
a liability risk for their effects on hERG, CYP2D6, and WI-38
cells, which appears to be due to the introduction of the second
nitrogen atom that can induce a toxic effect on the thiadiazole
core. The cytotoxicity of the compounds selected for
combination studies (4m, 4o, 3k, 4h) at 100 μM alone and in
combination with equimolar MTX was evaluated using THP-1
macrophage-like cells. Notably, no increase in toxicity was seen
in THP-1 cells for compound 4m (Figure 11). For the two
compounds active against TbPTR1 (4m and 4o), IC50 against
hERG, cytochrome P450, and mitochondrial toxicity were
determined (reported in Supporting Information). We observed
that the dose of compounds 4m, 4o, 4c, and 3k was 4 μM in the
potentiation assays. Therefore, considering the toxicity of the
compounds at 10 μM, we can extrapolate that only CYP1A2
shows around 50% of inhibition at 4 μM in the combination
studies. In the case of hERG, CYP2D6, CYP2A9, CYP2C19, and
mitochondrial toxicity, there is a selectivity index of around 3−4
fold, thus showing an acceptable profile.
■ CONCLUSIONS
In the present work, we have established an efficient platform to
identify and characterize hits for further development toward the
discovery of more potent antitrypanosomatidic agents. A
Figure 8. Dose−response curves for T. b. brucei growth inhibition for
compounds 4m (in blue), 4o (in red), 4h (in green), and 3k (in yellow)
in combination with equimolar amounts of MTX. The dose−response
curve for MTX alone is reported in purple (EC50 = 35 ± 3.0 μM). From
the dose−response curve, a measurable antiparasitic EC50 for the four
tested compounds (4m, EC50 = 8.6± 1.1 μM; 4o, EC50 = 17.5± 0.5 μM;
4h, EC50 = 35.6 ± 5.8 μM; and 3k, EC50 = 34.5 ± 3.2 μM) was
extrapolated. The dose−response curves are the merged curves from at
least two independent data sets done in triplicate, whereas the EC50
value in brackets represents the arithmetic average (±standard
deviation) of at least two independent assays.
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crystallization screen with a library of previously identified
inhibitors of LmPTR1 with a thiadiazole scaffold was performed,
and it resulted in structures of four new TbPTR1-cofactor-
inhibitor complexes, which guided the design of new thiadiazoles
in a structure-based approach. Compounds were synthesized and
evaluated for inhibitory activity against TbPTR1 and for
antiparasitic activity in a phenotypic assay against T. brucei.
Two of the best compounds yielded IC50 values of 16 and 25 μM
against TbPTR1 and share a 2,5-diamino-1,3,4-thiadiazole
scaffold. Compound 4c, a representative of this class, was
successfully crystallized in a ternary complex with TbPTR1
(TbPTR1−NADP+−4c), supporting the binding mode of the
earliest compounds (I−III). With respect to our starting
compounds, I−IV, we have improved the compounds’ biological
profiles, with 23 out of 57 compounds displaying a better PTR1
inhibition profile. Five compounds showed a better antiparasitic
effect with respect to I and IV.
In previous experiments performed on LmPTR1 thiadiazole
inhibitors, we have shown the combination effect with
pyrimethamine on promastigotes of L. infantum and mexicana.
This work specifically addressed the ability of TbPTR1 inhibitors
to potentiate the effect of the DHFR inhibitor MTX against T.
brucei by performing studies in combination with compounds 3k,
4h, 4o, and 4m. The potentiating effect was observed only with
the compounds inhibiting TbPTR1, 4o and 4m. In particular, we
focused on compound 4m, which showed the greatest inhibition
against the target enzyme, TbPTR1. When combined withMTX,
the EC50 of MTX against T. brucei improved 4.1 times (EC50
MTX alone 35 μM; EC50 MTX and 4m 8.6 μM). No increase in
the toxicity of the PTR1−DHFR inhibitor combination with
respect to the single compounds was observed. In addition, we
demonstrated that the potentiation activity of a PTR1 inhibitor
combined with MTX could be reversed through administration
of folic acid, the natural substrate of DHFR. The molecular
mechanism that might explain this reversal of inhibition is likely
complex and will be studied in future work. By adopting an
efficient early hit discovery platform, we showed that the 2-
amino-1,3,4-thiadiazole scaffold can be considered a promising
approach for the development of anti-T. brucei agents targeting
TbPTR1. Whereas the compounds show modest IC50 values
against both the enzymes and parasites in isolation, our results
suggest that combining the PTR1 inhibitors with DHFR
inhibitors provides a valid strategy for developing more potent
antiparasitic agents.
■ EXPERIMENTAL SECTION
Synthetic Chemistry. The chemical procedures and
characterization of all synthesized compounds and the respective
intermediates are reported in the Supporting Information.
X-ray Crystallography. TbPTR1-cofactor-inhibitor com-
plexes with I and II were prepared by incubating protein (6 mg/
mL, 1 mM NADPH, 10 mM dithiothreitol) with 2.5 μL of a 5
Figure 9. Effect of 1 mM folic acid (circles and dashed line) on T. b. brucei growth inhibition induced by MTX (A, reverse triangle and filled line) or the
equimolar combination of 4m + MTX (B, reverse triangle and filled line). The depicted dose−response curves are the merged curves from at least two
independent assays.
Figure 10. Summary heat map of the in vitro assays to determine possible liability issues for all synthesized compounds. Assays were performed to assess
inhibition of hERG and five CYP isoforms (1A2, 2C9, 2C19, 2D6, and 3A4), growth inhibition of A549 andW1-38 cell lines, and mitochondrial toxicity
at 10 μM. The hDHFR inhibition was determined at 100 μM. The data, expressed as percentage values, were organized by adopting a color code for
rapid and intuitive visualization. The ideal compound should have all tiles blue, indicating a safe toxicological profile for progressing into the
development pipeline. The cells are colored from blue (100% of cell growth at the tested concentration) to red (0% of cell growth at the tested
concentration) for A549 andW1-38 and from blue (0% of inhibitory activity at the tested concentration) to red (100% of inhibitory activity at the tested
concentration) for CYP isoforms, hERG, hDHFR, and mitochondrial toxicity.
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mM solution of inhibitor in dimethylsulfoxide (DMSO) in 20
mM Tris-HCl pH 7.5 on ice for 1 h before crystallization.
Hanging drops (1.5 μL of protein solution and 1.5 μL of
reservoir) were incubated over 1 mL of reservoir (2.7 M sodium
acetate, 10 mM sodium citrate pH 4.5). Crystals grew at 20 °C in
a few days. Complexes with compounds III, IV, and 4c were
obtained by soaking the preformed crystals of a TbPTR1−
cofactor binary complex obtained in sitting drops equilibrated
against reservoir (1.5−2.5 M sodium acetate and 100 mM
sodium citrate pH 5.0). The crystals were soaked for 4−6 h in the
crystallization buffer containing 2−4 mM of each compound
dissolved in DMSO (without exceeding a DMSO/crystal
solution ratio of 1:9). The crystals were transferred in a cryo-
protectant (precipitant plus 30% glycerol) and flash-frozen in
liquid nitrogen or taken directly from mother liquor and flash-
cooled. Data were recorded using a Rigaku MicroMax 007
rotating anode and an R-AXIS IV++ dual image plate detector
system at the European Synchrotron Radiation Facility
(Grenoble, France) on beamline BM30A with an ADSC
Q315r detector, at the Diamond Light Source (Didcot, UK)
on beamline I04 with a PILATUS 6M-F detector, or at the Elettra
Synchrotron (Trieste, Italy) on beamline XRD1with a PILATUS
2M detector. Data were processed with MOSFLM41 or XDS42
and then scaled with SCALA43 with the CCP4 software suite.44
The structures were solved by molecular replacement45 using
TbPTR1 (PDB: 2X9G) as the starting model.27 Rigid body
refinement and rounds of restrained refinement were carried out
using REFMAC5.46 Inspection of electron density, model
manipulation, and identification of solvent, ions, and ligands
were done using COOT.47 Figures were generated with
CCP4mg.48 The coordinates and structure factors were
deposited in the Protein Data Bank (PDB) under accession
codes 2YHI, 2YHU, 4WCD, 4WCF, and 5IZC for compounds I,
II, III, IV, and 4c, respectively. InTbPTR1−II andTbPTR1−III,
Cys168 is chemically modified to S-oxycysteine (defined as CSX)
indicative of a reactive cysteine (see Figure 2B,C).
Computational Docking. The three-dimensional (3D)
structures of the compounds were created from SMILES strings
and optimized with the OPLS_2005 force field49 using Maestro
(Schrödinger, LLC).50 Ligand preparation included the
generation of stereoisomers (up to eight) and low-energy ring
conformations (one per compound) as well as determination of
ionization states and tautomers for pH 7.0 ± 0.5 using Epik.
Highly conserved structural water was identified by the WatCH
clustering approach.51 Briefly, 99 chains from TbPTR1 crystal
structures (see Table S5 for a list of structures) were
superimposed, and their crystallographic water positions were
clustered with a distance criterion of 2.4 Å for considering
identical water oxygen positions. Seventeen water sites with at
least 50% conservation were considered to be conserved.
TbPTR1 receptors for docking and SiteMap analysis52 were
composed of chain A of the respective crystal structure and a C-
terminal tripeptide from the neighboring subunit, Val266 to
Ala268, pointing into the active site of chain A. Crystallographic
solvent molecules were removed and replaced with conserved
water molecules (from WatCH clustering) for docking studies.
SiteMap calculations were conducted with PDB IDs 2YHI,
2YHU, 4WCD, and 4WCF. Docking was carried out to PDB ID
2X9G.27 Bond-order assignment and hydrogen atom addition
was done with PrepWizard.49 N- and C-termini of chain A were
capped with N-acetyl and N-methyl amide groups, respectively.
The NADP+ cofactor protonation state was computed at pH 7.0
± 0.5. Protein protonation states were assigned for pH 7.0 using
PROPKA.53 The H-bond network was optimized, and all
hydrogens were subjected to a restrained minimization. For
the SiteMap analysis, the site was defined by the thiadiazole core
moiety of the ligand. A surrounding region of 3 Å was examined.
Ten site points were required per reported site, and site maps
were cropped at 3 Å from their nearest site point. Otherwise,
standard values were used. For docking, a 20 Å × 20 Å × 20 Å
docking grid was centered on Phe97. The hydroxyl groups of
Ser95, Cys168, Tyr174, and NADP+ ribose were set rotatable.
Docking was performed with Glide (Schrödinger, LLC)54−56
using the SP protocol (standard precision). Themaximum ligand
size and rotatable bond count were kept at standard values. A
scaling factor of 0.80 for the ligand van der Waals radii and a
partial charge cutoff of 0.15 were used. Ligands were treated as
flexible, nitrogen inversions, and ring conformations were
sampled. Nonplanar conformations were penalized when
performing bias sampling of amide torsions. Epik state penalties
were added to the docking score; intramolecular hydrogen bonds
were rewarded; and conjugated π group planarity was enhanced.
Twenty poses per ligand were subjected to postdocking energy
minimization, employing a pose rejection threshold of 0.5 kcal/
mol. Up to 10 final solutions were collected.
The validation of the docking protocol was based on cross-
docking studies of the crystallized compounds I, II, III, IV, and
4c. As shown in Table S6 and as discussed in the “Docking
Validation section” of the Supporting Information, near-native
poses were overall reproduced with the current protocol and
typically found within 0.3 kcal/mol of the best-scoring docking
solution, as ranked by the docking score. Poses were therefore
ranked by the Glide docking score, and all poses within 1.0 kcal/
mol of the top scoring solution were further analyzed. A visual
inspection of the interaction pattern and comparison with crystal
structures 3BMC (TbPTR1 in complex with folate) and 5IZC
(TbPTR1 in complex with 4c) were used to select the most likely
Figure 11. Toxicity against THP-1 cells for selected thiadiazoles 3k, 4h,
4m, and 4o (in blue), MTX (in red), and equimolar combinations of
thiadiazoles and MTX at 100 μM (in green). The data presented are the
average ± standard deviation from at least two independent experi-
ments.
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poses on the basis of experimental evidence. Docking results are
also given in Table S7 in the Supporting Information.
Biological Assays. Protein Expression and Purification.
TbPTR1, LmPTR1, TbDHFR, LmDHFR, and hDHFR were
obtained and purified as reported in our previous work.32 The
kinetic characterization (Km and kcat) of the enzymes is reported
in Table S8 of the Supporting Information.
TbPTR1, LmPTR1, TbDHFR, LmDHFR, and hDHFR
Enzyme Assays. The thiadiazoles were a small part of a library
of many thousands of molecules that we tested within the three-
year European project NMTrypI (http://fp7-nmtrypi.eu).
Because of the sharing of technologies within the NMTrypI
platform, we were able to perform the enzymatic studies against
TbPTR1 and LmPTR1 and the early-toxicity assays by HTS
methodologies. The in vitro assays used in the current study were
based upon those reported in the literature, and the kinetic data
are comparable (Table S8).34 Because PTR1 enzymes use H2B as
a substrate and also require NADPH for the reaction, the
reduction of H2B to H4B by PTR1 is nonenzymatically linked
with the reduction of cytochrome c in this assay, which is
detected at 550 nm. The formation of cyt c Fe2+ results in a signal
increase in the photometric readout.
TbPTR1 and LmPTR1 activities were assayed in a buffer
containing 20 mM sodium citrate (pH 6.0). The final reaction
mixture contained the test compound in a range of
concentrations and TbPTR1/LmPTR1 (6.0 nM/12.0 nM),
H2B (0.3 μM/3.0 μM), cytochrome c (100 μM/100 μM), and
NADPH (500 μM/500 μM). The final assay volume was 50 μL
in 384-well clear plates (Greiner Bio-One, 781101). Compound
screening was performed by addition of the compound to assay
plates (in 100% DMSO), followed by addition of 45 μL reaction
mix (enzyme, H2B, and cytochrome c in 20 mM sodium citrate
buffer). A preread was made at 550 nm using an EnVision
Multilabel Reader 2103 (PerkinElmer Inc, US), followed by
incubation of the assay plates at 30 °C for 10 min. The reaction
was initiated by addition of 5 μL of NADPH (from a stock at 5
mM in ultrapure water), followed by kinetically reading the assay
plates at 550 nm using the EnVision Multilabel Reader at 10, 20,
30, 40, and 50 min and calculating the slope of the reaction in
each well. The screening data were analyzed using ActivityBase
(IDBS), and for outlier elimination in the control wells, the 3-
sigma method was applied. On the basis of the slope, data were
normalized to the positive control MTX for TbPTR1/LmPTR1
(1 μM/50 μM, yielding 100% inhibition) and negative controls
(1% DMSO, yielding 0% inhibition), and % inhibition was
calculated for all samples. The measurement at time 0 min was
used to flag the interfering samples. Each compound was tested
in triplicate, and the pIC50 value, standard deviation, Hill slope,
and minimum signal and maximum signal for each dose−
response curve were obtained using a four-parameter logistic fit
in the XE module of ActivityBase (IDBS). Compounds
displaying a percentage of inhibition against TbPTR1 above
30% at 50 μM were further analyzed at concentrations from
0.001 to 100 μM for the determination of IC50. The IC50 value of
pyrimethamine (IC50 = 0.09 μM against TbPTR1), a DHFR
inhibitor also able to inhibit PTR1, was measured routinely as a
standard. However, not all compounds selected gave measurable
IC50 in the dose−response assays. LmDHFR, TbDHFR, and
hDHFR activities were assessed spectrophotometrically as
previously described, and the values for the kinetic constants
characterizing each enzyme (Km) were comparable to literature
values (Table S8).22
hERG Cardiotoxicity Assay. This assay made use of
Invitrogen’s Predictor hERG fluorescence polarization (FP)
assay. The assay uses a membrane fraction containing the hERG
channel (Predictor hERG membrane) and a high-affinity red
fluorescent hERG channel ligand or “tracer” (Predictor hERG
Tracer Red), whose displacement by test compounds can be
determined in a homogenous, FP-based format.32
Cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4
Assays. These assays made use of the Promega P450-Glo assay
platform. Each CYP450 assay made use of microsomal
preparations of cytochromes from baculovirus-infected insect
cells. Action of the CYP450 enzymes on each substrate ultimately
resulted in the generation of light, and a decrease in this was
indicative of inhibition of the enzyme.32
Cytotoxicity Assay against A549 and W1-38 Cells. The
assays were performed using the CellTiter-Glo assay from
Promega. The assay detects cellular ATP content, with the
amount of ATP being directly proportional to the number of cells
present. The A549 cells were obtained from DSMZ (German
Collection of Microorganisms and Cell Cultures, Braunschweig,
Germany) and W1-38 cells were obtained from ATCC (ATCC
CCL-75) and were grown in Dulbecco’s modified Eagle medium
(DMEM) with fetal calf serum (FCS) (10% v/v), streptomycin,
(100 μg/mL) and penicillin G (100 U/mL).32
Assessment of Mitochondrial Toxicity. This assay made
use of MitoTracker Red chloromethyl-X-rosamine (CMXRos)
uptake and high content imaging to monitor compound-
mediated mitochondrial toxicity in the 786-O (renal carcinoma)
cell line. Cells were maintained using the Roswell Park Memorial
Institute (RPMI)-1640 medium containing 2 mM glutamine,
FCS (10% v/v), streptomycin (100 μg/mL), and penicillin G
(100 U/mL).32
In Vitro Evaluation of Activity against T. brucei. The
assay relies on indirect determination of parasite population
viability by quantification of total DNA present in the well using
the SYBR Green I DNA fluorescent dye. Briefly, the assay
consisted of incubating bloodstream forms of the T. b. brucei
Lister 427 strain in the presence of compounds for 72 h, followed
by cell lysis and addition of the SYBRGreen I dye.57 Pentamidine
at 120 nMwas used as the reference compound showing an EC50
of 3.8 ± 0.48 nM comparable with the value reported in the
literature.58 DMSO-treated parasites were used as negative
controls and pentamidine-treated parasites and blank wells
(without parasites) were used as positive controls. Compounds
and controls were plated in a semiautomated process that utilizes
the liquid handler Janus MDT (PerkinElmer), which is equipped
with a 384 pipetting head capable of dispensing a minimum
volume of 0.5 μL. As T. b. brucei is sensitive to DMSO and
tolerates a maximum of approximately 1% DMSO, compound
libraries dissolved in 100% DMSO must be diluted at least 200-
fold with the aid of “intermediate plates”. Following compound
plating in the final assay plate, 50 μL of a parasite suspension at
8000 trypanosomes/mL was seeded to the assay and control
plates and incubated for 72 h at 37 °C and 5% CO2. At the assay
endpoint, 15 μL of the lysis solution (30 mM Tris-HCl pH 7.5,
7.5 mM EDTA, 0.012% saponin, and 0.12% Triton X-100) was
added to the plates containing 0.5 μL of SYBRGreen I (10 000×,
Life Technologies) per 1 mL of lysis solution. The plates were
shaken for 30 s at 800 rpm in a MixMate (Eppendorf) and
incubated for 1 h in the dark at room temperature. The plates
were then read for fluorescence at the microplate reader
EnVision (PerkinElmer). Compounds that yielded >80%
inhibition of parasite growth at 50 μM were selected for EC50
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determinations. However, not all selected compounds gave
reliable EC50 data in the dose−response assay.
In Vitro Evaluation of Activity against T. brucei for MTX
Potentiation Assays and Folic Acid Supplementation
Experiment. T. b. brucei Lister 427 bloodstream forms were
grown at 37 °C and 5% CO2 in a complete HMI-9 medium,
supplemented with 10% FCS and 100 UI/mL of penicillin/
streptomycin. The cultures were diluted until a cell density of 2×
106/mLwas reached. The efficacy of compounds againstT. brucei
bloodstream forms was evaluated using a modified resazurin-
based assay previously described.46 The compounds were
prepared from a stock solution in 10 mM DMSO and diluted
in HMI-9 (supplemented or not with 1 mM folic acid, Sigma-
Aldrich) to 40 μMwork solution (0.4% DMSO, with the DMSO
limit in the assay being 0.4%). For the combination assays, 40 μM
equimolar mixture was prepared using 20 μM test compound
and 20 μM MTX. The 40 μM work solution was then used to
perform serial dilutions (1:2) in a 96-well plate. Upon compound
addition to the test plate, the mid-log bloodstream forms were
added (100 μL) in complete HMI-9 medium (supplemented or
not with 1 mM folic acid) at a final cell density of 1× 104/mL in a
final well volume of 200 μL with a maximum DMSO
concentration of 0.2%. Following incubation for 72 h at 37 °C
and 5% CO2, 20 μL of 0.5 mM resazurin solution was added, and
the plates were incubated further for 4 h under the same
conditions. Fluorescence was measured at 540 and 620 nm
excitation and emission wavelengths, respectively, using a
Synergy 2 multi-mode reader (BioTek). The antitrypanosomatid
effect was evaluated by the determination of the IC50 value
(concentration required to inhibit growth by 50%) and
calculated by the nonlinear regression analysis using GraphPad
Prism version 5.00 for Windows, GraphPad Software, San Diego,
California, USA (www.graphpad.com). It was not possible to
analyze the combination of 4m with MTX by adopting an
isobologram approach, as described by Chou.59 This approach
requires the use of both compounds at their EC50 potency in the
combination, which is impossible to be detected for compound
4m having no intrinsic antiparasitic activity as a single agent at the
tested concentrations. Folic acid (1 mM)was chosen on the basis
of the following experiments. The stock solution of 10 mM folic
acid dissolved in NaOH solution was used to perform a dose−
response curve with folic acid alone to evaluate the maximum
amount we could use without compromising parasite growth due
to pH modification of the media. The highest concentration that
we could use was 1 mM without interfering with the parasite
growth or significantly changing the pH of the media. The IC50
values reported are the averages of the results obtained in at least
two independent experiments. Pentamidine was used as the
reference drug and internal control in all assays. The average
pentamidine EC50 for the assays was 2.28 ± 1.18 nM.
Cytotoxicity Assessment against THP-1 Macrophages.
The effect of compounds 3k, 4h, 4m, and 4o on THP-1-derived
macrophages was assessed by the colorimetric MTT assay [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide].
Briefly, 1× 106 THP-1 cells were differentiated intomacrophages
by addition of 20 ng/mL of phorbol-myristate 13-acetate (PMA,
Sigma-Aldrich) for 18 h, followed by replacement with a fresh
medium and further incubation for 24 h. The cells were
incubated with compounds ranging from 100 to 3 μM after
dilution in the RPMI complete medium containing a maximum
amount of 1% DMSO. After incubation for 72 h at 37 °C and 5%
CO2, the medium was removed and 0.5 mg/mL MTT solution
was added. The plates were incubated for 4 additional hours to
allow viable cells to convert MTT into a purple formazan
product. Solubilization of formazan crystals was achieved by
addition of 2-propanol, and absorbance was read at 570 nm using
a Synergy 2 multi-mode reader (BioTek). Cytotoxicity was
evaluated by the determination of the CC50 value (drug
concentration that reduced the percentage of viable cells by
50%) and calculated by the nonlinear regression analysis using
GraphPad Prism version 5.00 for Windows, GraphPad Software,
San Diego, California, USA (www.graphpad.com).
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